Your browser doesn't support javascript.
loading
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
Okamoto, W; Sakai, K; Makiyama, A; Yamamoto, Y; Shitara, K; Denda, T; Izawa, N; Nakano, Y; Nishina, T; Esaki, T; Hara, H; Miura, Y; Boku, N; Yamazaki, K; Hironaka, S; Misumi, T; Hyodo, I; Muro, K; Nishio, K.
Affiliation
  • Okamoto W; Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama; Translational Research Support Section, National Cancer Center Hospital East, Kashiwa; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa; Cancer Treatment Cen
  • Sakai K; Department of Genome Biology, Kindai University Faculty of Medicine, Osakasayama.
  • Makiyama A; Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu; Cancer Center, Gifu University Hospital, Gifu.
  • Yamamoto Y; Department of Gastroenterology, University of Tsukuba Hospital, Tsukuba.
  • Shitara K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya.
  • Denda T; Division of Gastroenterology, Chiba Cancer Center, Chiba.
  • Izawa N; Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki.
  • Nakano Y; Department of Medical Oncology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya.
  • Nishina T; Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama.
  • Esaki T; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka.
  • Hara H; Department of Gastroenterology, Saitama Cancer Center, Kitaadachi-gun.
  • Miura Y; Department of Medical Oncology, Toranomon Hospital, Minato-ku.
  • Boku N; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo.
  • Yamazaki K; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun.
  • Hironaka S; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Yufu.
  • Misumi T; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama.
  • Hyodo I; Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama.
  • Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Nishio K; Department of Genome Biology, Kindai University Faculty of Medicine, Osakasayama. Electronic address: knishio@med.kindai.ac.jp.
ESMO Open ; 7(6): 100592, 2022 12.
Article in En | MEDLINE | ID: mdl-36502778
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Colonic Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: ESMO Open Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Colonic Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: ESMO Open Year: 2022 Document type: Article